Condition: Pain, Postoperative · Hernia, Ventral · Abdominoplasty · Sponsor: Innocoll
This is a multicenter, Phase 3, open-label, safety, tolerability, and characterization of pharmacokinetics study of the INL 001 (bupivacaine HCl) implant, at 300 mg, in patients following various soft-tissue surgeries: open ventral hernia repair, abdominoplasty, open abdominal hysterectomy, laparoscopic-assisted colectomy, and reduction mammoplasty.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| North Alabama Medical Center | Florence, Alabama, United States | — |
| Helen Keller Hospital | Sheffield, Alabama, United States | — |
| Lotus Clinical Research | Pasadena, California, United States | — |
| Midwest Clinical Research | Dayton, Ohio, United States | — |
| Daneshvari Solanki | Houston, Texas, United States | — |
| Baylor College of Medicine | Houston, Texas, United States | — |
| Memorial Hermann | Houston, Texas, United States | — |
| Endeavor Clinical Trials | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04785638